Patent · US Active

CFTR MRNA compositions and related methods and uses

US11510937B2 · kind B2 · utility

0Cited by

251References

13Claims

0Family size

Assignees

TRANSLATE BIO, INC. · US
ethris GmbH · DE

Inventors

Michael Heartlein · Boxborough, US
Braydon Charles Guild · Concord, US
Frank DeRosa · Lexington, US
Carsten Rudolph · Krailling, DE
Christian Plank · Wien, AT
Lianne Smith · Lexington, US

Key dates

Filing date	Aug 14, 2019
Grant date	Nov 29, 2022
Priority date	—
Expiry date	Jun 22, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y306/03049
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to materials, formulations, production methods, and methods for delivery of CFTR mRNA, including but not limited to chemically modified mRNA for induction of CFTR expression, including in the mammalian lung. The present invention is particularly useful for treating cystic fibrosis, but is also useful in the treatment of diseases related to CFTR gene.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.